Pandemic vaccines: promises and pitfalls

Area of Science:

• Virology
• Immunology
• Public Health

Background:

• Influenza A/H5N1 prototype vaccines may exhibit poor immunogenicity, potentially requiring multiple doses for protective neutralizing antibody levels.
• The precise antibody thresholds for protection against highly pathogenic avian influenza strains are not fully established.
• Global vaccine manufacturing capacity, while substantial, may be insufficient to meet pandemic demand, especially with high antigen requirements.

Purpose of the Study:

• To evaluate the immunogenicity and protective potential of prototype influenza A/H5N1 vaccines.
• To assess the antibody levels required for protection against a severe influenza A/H5N1 challenge.
• To consider the implications of vaccine manufacturing capacity and timelines for pandemic preparedness.

Main Methods:

• Evaluation of prototype influenza A/H5N1 vaccines for immunogenicity.
• Assessment of neutralizing antibody levels in relation to protective immunity.
• Analysis of global vaccine production capacity and pandemic response strategies.

Main Results:

• Prototype A/H5N1 vaccines may require two or more doses to achieve protective antibody levels.
• The exact protective antibody levels against severe influenza A/H5N1 are currently unknown.
• Limited vaccine availability necessitates reliance on other control measures during the early pandemic phase.

Conclusions:

• Pandemic influenza vaccines should prioritize preventing death over preventing infection.
• International coordination is crucial for evaluating and registering new pandemic vaccines efficiently.
• Non-vaccine interventions remain critical in the initial 3-6 months of a pandemic before widespread vaccine availability.